Copyright Reports & Markets. All rights reserved.

Global Endocrine Therapy Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Endocrine Therapy Drugs for Breast Cancer Market Overview

    • 1.1 Product Overview and Scope of Endocrine Therapy Drugs for Breast Cancer
    • 1.2 Classification of Endocrine Therapy Drugs for Breast Cancer by Types
      • 1.2.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Endocrine Therapy Drugs for Breast Cancer Revenue Market Share by Types in 2018
      • 1.2.3 Tamoxifen
      • 1.2.4 Anastrozole
      • 1.2.5 Exemestane
      • 1.2.6 Letrozole
      • 1.2.7 Goserelin
      • 1.2.8 Fulvestrant
    • 1.3 Global Endocrine Therapy Drugs for Breast Cancer Market by Application
      • 1.3.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Hospital
      • 1.3.3 Clinic
      • 1.3.4 Drug Center
      • 1.3.5 Other
    • 1.4 Global Endocrine Therapy Drugs for Breast Cancer Market by Regions
      • 1.4.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Endocrine Therapy Drugs for Breast Cancer (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Teva
      • 2.1.1 Business Overview
      • 2.1.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Teva Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Amneal Pharms
      • 2.2.1 Business Overview
      • 2.2.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Amneal Pharms Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 AstraZeneca
      • 2.3.1 Business Overview
      • 2.3.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 AstraZeneca Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Novartis
      • 2.4.1 Business Overview
      • 2.4.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Novartis Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Intas Pharmaceuticals
      • 2.5.1 Business Overview
      • 2.5.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Intas Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Chemo
      • 2.6.1 Business Overview
      • 2.6.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Chemo Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Accure Labs
      • 2.7.1 Business Overview
      • 2.7.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Accure Labs Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Natco
      • 2.8.1 Business Overview
      • 2.8.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Natco Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Zydus Pharmaceuticals
      • 2.9.1 Business Overview
      • 2.9.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Zydus Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Sanofi
      • 2.10.1 Business Overview
      • 2.10.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Sanofi Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Pfizer
      • 2.11.1 Business Overview
      • 2.11.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Pfizer Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 Mylan
      • 2.12.1 Business Overview
      • 2.12.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 Mylan Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Wockhardt
      • 2.13.1 Business Overview
      • 2.13.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Wockhardt Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 Cipla
      • 2.14.1 Business Overview
      • 2.14.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Cipla Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.15 Actiza Pharmaceutical
      • 2.15.1 Business Overview
      • 2.15.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 Actiza Pharmaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.16 Hikma Pharmaceuticals
      • 2.16.1 Business Overview
      • 2.16.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.16.2.1 Product A
        • 2.16.2.2 Product B
      • 2.16.3 Hikma Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.17 Shanghai Forward Technology
      • 2.17.1 Business Overview
      • 2.17.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.17.2.1 Product A
        • 2.17.2.2 Product B
      • 2.17.3 Shanghai Forward Technology Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.18 Bayer
      • 2.18.1 Business Overview
      • 2.18.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.18.2.1 Product A
        • 2.18.2.2 Product B
      • 2.18.3 Bayer Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.19 Liaoning Kangtai Pharmaceutical
      • 2.19.1 Business Overview
      • 2.19.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.19.2.1 Product A
        • 2.19.2.2 Product B
      • 2.19.3 Liaoning Kangtai Pharmaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.20 Fu 'an Pharmaceutical Group
      • 2.20.1 Business Overview
      • 2.20.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.20.2.1 Product A
        • 2.20.2.2 Product B
      • 2.20.3 Fu 'an Pharmaceutical Group Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.21 Apotex
      • 2.21.1 Business Overview
      • 2.2.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.21.2.1 Product A
        • 2.21.2.2 Product B
      • 2.21.3 Apotex Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.22 Taro
      • 2.22.1 Business Overview
      • 2.22.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.22.2.1 Product A
        • 2.22.2.2 Product B
      • 2.22.3 Taro Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.23 Sun Phamaceutical
      • 2.23.1 Business Overview
      • 2.23.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.23.2.1 Product A
        • 2.23.2.2 Product B
      • 2.23.3 Sun Phamaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.24 Intas Pharmaceuticals
      • 2.24.1 Business Overview
      • 2.24.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.24.2.1 Product A
        • 2.24.2.2 Product B
      • 2.24.3 Intas Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.25 Chemo
      • 2.25.1 Business Overview
      • 2.25.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.25.2.1 Product A
        • 2.25.2.2 Product B
      • 2.25.3 Chemo Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.26 Accure Labs
      • 2.26.1 Business Overview
      • 2.26.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.26.2.1 Product A
        • 2.26.2.2 Product B
      • 2.26.3 Accure Labs Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
    • 2.27 Sun Pharmaceutical
      • 2.27.1 Business Overview
      • 2.27.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
        • 2.27.2.1 Product A
        • 2.27.2.2 Product B
      • 2.27.3 Sun Pharmaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Endocrine Therapy Drugs for Breast Cancer Market Competition, by Players

    • 3.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Endocrine Therapy Drugs for Breast Cancer Players Market Share
      • 3.2.2 Top 10 Endocrine Therapy Drugs for Breast Cancer Players Market Share
    • 3.3 Market Competition Trend

    4 Global Endocrine Therapy Drugs for Breast Cancer Market Size by Regions

    • 4.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue and Market Share by Regions
    • 4.2 North America Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 4.5 South America Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    5 North America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

    • 5.1 North America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 5.2 USA Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    6 Europe Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

    • 6.1 Europe Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 6.2 Germany Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 6.3 UK Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 6.4 France Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

    • 7.1 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 7.2 China Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 7.5 India Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    8 South America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

    • 8.1 South America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 8.2 Brazil Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Endocrine Therapy Drugs for Breast Cancer by Countries

    • 9.1 Middle East and Africa Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

    10 Global Endocrine Therapy Drugs for Breast Cancer Market Segment by Type

    • 10.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Endocrine Therapy Drugs for Breast Cancer Market Forecast by Type (2019-2024)
    • 10.3 Tamoxifen Revenue Growth Rate (2014-2024)
    • 10.4 Anastrozole Revenue Growth Rate (2014-2024)
    • 10.5 Exemestane Revenue Growth Rate (2014-2024)
    • 10.6 Letrozole Revenue Growth Rate (2014-2024)
    • 10.7 Goserelin Revenue Growth Rate (2014-2024)
    • 10.8 Fulvestrant Revenue Growth Rate (2014-2024)

    11 Global Endocrine Therapy Drugs for Breast Cancer Market Segment by Application

    • 11.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue Market Share by Application (2014-2019)
    • 11.2 Endocrine Therapy Drugs for Breast Cancer Market Forecast by Application (2019-2024)
    • 11.3 Hospital Revenue Growth (2014-2019)
    • 11.4 Clinic Revenue Growth (2014-2019)
    • 11.5 Drug Center Revenue Growth (2014-2019)
    • 11.6 Other Revenue Growth (2014-2019)

    12 Global Endocrine Therapy Drugs for Breast Cancer Market Size Forecast (2019-2024)

    • 12.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size Forecast (2019-2024)
    • 12.2 Global Endocrine Therapy Drugs for Breast Cancer Market Forecast by Regions (2019-2024)
    • 12.3 North America Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
    • 12.4 Europe Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
    • 12.6 South America Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Scope of the Report:
      The global Endocrine Therapy Drugs for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Endocrine Therapy Drugs for Breast Cancer.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Endocrine Therapy Drugs for Breast Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Endocrine Therapy Drugs for Breast Cancer market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Teva
      Amneal Pharms
      AstraZeneca
      Novartis
      Intas Pharmaceuticals
      Chemo
      Accure Labs
      Natco
      Zydus Pharmaceuticals
      Sanofi
      Pfizer
      Mylan 
      Wockhardt
      Cipla
      Actiza Pharmaceutical
      Hikma Pharmaceuticals
      Shanghai Forward Technology
      Bayer
      Liaoning Kangtai Pharmaceutical
      Fu 'an Pharmaceutical Group
      Apotex
      Taro
      Sun Phamaceutical
      Intas Pharmaceuticals
      Chemo
      Accure Labs
      Sun Pharmaceutical

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Tamoxifen
      Anastrozole
      Exemestane
      Letrozole
      Goserelin
      Fulvestrant

      Market Segment by Applications, can be divided into
      Hospital
      Clinic
      Drug Center
      Other

      Buy now